AKShare - Stock Data - Detailed Records of Senior Executives' Shareholding Changes

Author’s Message This update introduces the stock data interface for detailed records of senior executives’ shareholding changes. Detailed records of senior executives’ shareholding changes refer to transaction logs documenting purchases and sales of company shares by top-level management personnel—such as CEOs, CFOs, and board members. These records hold reference value for investors, as executives, being insiders, possess deeper insights into the company’s operational status and future prospects. By analyzing executives’ trading behavior, investors can gauge internal confidence in the company and assess its future outlook. Such detailed records typically include the following information: 1. Transaction Date: The specific date on which the executive bought or sold shares. 2. Executive Name: The full name of the executive conducting the share transaction. 3. Executive Position: The executive’s role within the company—for example, CEO, CFO, etc. 4. Transaction Type: The nature of the share transaction—primarily categorized as purchase, sale, or grant. 5. Transaction Price: The price per share at which the executive bought or sold. 6. Transaction Volume: The number of shares bought or sold. 7. Post-Transaction Holdings: The total number of shares held by the executive after the transaction. By analyzing these detailed records, investors can glean the following insights: 1. Executive Confidence: A significant volume of share purchases by executives over a given period may signal strong confidence in the company’s future development; conversely, large-scale share sales may indicate caution regarding the company’s prospects. 2. Insider Information: Shareholding changes by executives may reflect non-public information. For instance, if an executive purchases shares shortly before the company announces major positive news, it may suggest prior knowledge of such developments. 3. Equity Incentives: Grant-type transactions often relate to the company’s equity incentive programs—for example, stock options or restricted stock awards designed to align executive performance with corporate goals. In summary, detailed records of senior executives’ shareholding changes constitute an important information source for investors, aiding in the assessment of internal confidence and future growth potential. However, investors should bear in mind that such changes are not decisive indicators; comprehensive analysis must also incorporate financial statements, market conditions, and other relevant factors. Related video tutorials have been released: “AKShare – Beginner Level – Usage Guide”, “AKShare – Beginner Level – Practical Applications”, “AKShare – Source Code Analysis”, and “Open-Source Project Spotlight”. For course descriptions and subscription details, please click “Read Original Article”! The AKShare VIP Discussion Group warmly welcomes you! To join, reply “Join Group” in the official WeChat account. Updated Interface: ・ "stock_hold_management_detail_cninfo" # Detailed Records of Senior Executives’ Shareholding Changes Interface: stock_hold_management_detail_cninfo Target URL: webapi.cninfo.com.cn/#... Description: China Securities Regulatory Commission (CSRC) Information Network – Data Center – Thematic Statistics – Shareholders & Capital Structure – Detailed Records of Senior Executives’ Shareholding Changes

China Dichloroisopropyl Ether Market Development Trends and Outlook Analysis Report: 2023 vs. 2029

5.3.3 LyondellBasell: Dichloroisopropyl Ether Sales Volume, Revenue, Pricing, and Gross Margin (2019–2022) 5.3.4 LyondellBasell Company Profile and Core Business Activities 5.3.5 Latest Corporate Developments at LyondellBasell 5.4 Seqens 5.4.1 Seqens: Basic Information, Dichloroisopropyl Ether Production Facilities, Sales Regions, Competitors, and Market Position 5.4.2 Seqens: Dichloroisopropyl Ether Product Specifications, Technical Parameters, and Market Applications 5.4.3 Seqens: Dichloroisopropyl Ether Sales Volume, Revenue, Pricing, and Gross Margin (2019–2022) 5.4.4 Seqens Company Profile and Core Business Activities 5.4.5 Latest Corporate Developments at Seqens 5.5 TKM Pharma 5.5.1 TKM Pharma: Basic Information, Dichloroisopropyl Ether Production Facilities, Sales Regions, Competitors, and Market Position 5.5.2 TKM Pharma: Dichloroisopropyl Ether Product Specifications, Technical Parameters, and Market Applications 5.5.3 TKM Pharma: Dichloroisopropyl Ether Sales Volume, Revenue, Pricing, and Gross Margin (2019–2022) 5.5.4 TKM Pharma Company Profile and Core Business Activities 5.5.5 Latest Corporate Developments at TKM Pharma 5.6 INEOS 5.6.1 INEOS: Basic Information, Dichloroisopropyl Ether Production Facilities, Sales Regions, Competitors, and Market Position 5.6.2 INEOS: Dichloroisopropyl Ether Product Specifications, Technical Parameters, and Market Applications 5.6.3 INEOS: Dichloroisopropyl Ether Sales Volume, Revenue, Pricing, and Gross Margin (2019–2022) 5.6.4 INEOS Company Profile and Core Business Activities 5.6.5 Latest Corporate Developments at INEOS 5.7 Sasol 5.7.1 Sasol: Basic Information, Dichloroisopropyl Ether Production Facilities, Sales Regions, Competitors, and Market Position 5.7.2 Sasol: Dichloroisopropyl Ether Product Specifications, Technical Parameters, and Market Applications 5.7.3 Sasol: Dichloroisopropyl Ether Sales Volume, Revenue, Pricing, and Gross Margin (2019–2022) 5.7.4 Sasol Company Profile and Core Business Activities 5.7.5 Latest Corporate Developments at Sasol 5.8 Dor Group 5.8.1 Dor Group: Basic Information, Dichloroisopropyl Ether Production Facilities, Sales Regions, Competitors, and Market Position 5.8.2 Dor Group: Dichloroisopropyl Ether Product Specifications, Technical Parameters, and Market Applications 5.8.3 Dor Group: Dichloroisopropyl Ether Sales Volume, Revenue, Pricing, and Gross Margin (2019–2022) 5.8.4 Dor Group Company Profile and Core Business Activities 5.8.5 Latest Corporate Developments at Dor Group 5.9 Dow Chemical 5.9.1 Dow Chemical: Basic Information, Dichloroisopropyl Ether Production Facilities, Sales Regions, Competitors, and Market Position 5.9.2 Dow Chemical: Dichloroisopropyl Ether Product Specifications, Technical Parameters, and Market Applications 5.9.3 Dow Chemical: Dichloroisopropyl Ether Sales Volume, Revenue, Pricing, and Gross Margin (2019–2022)

Sasol CFO Sells 1,798 Shares of Stock

Oct 1, 2026

Sasol's CFO Walt Paul Bruns sold 1,798 shares worth $25,423.72, reducing holdings by 3.18%. The company recently reported quarterly EPS of $0.56 on revenue of $4.61 billion.

MarketBeat

2026-09-25

Sasol CEO Simon Baloyi Receives Stock Award, Sells Majority Shortly After

2026-09-25

Sasol CFO Walt Paul Bruns Acquires Shares, Then Sells 7,890 on Vesting

2026-09-25

Sasol CFO Sells $100,203 in Stock

2026-10-01

Sasol CFO Sells 1,798 Shares of Stock

2026-10-01

Sasol CFO Acquires and Sells Shares Following Stock Award Vesting